Table 1 Clinicopathological characteristics of patients with primary operable breast cancer
From: MCL-1 is a prognostic indicator and drug target in breast cancer
Clinicopathological characteristics (total) | Patients (n%) |
|---|---|
Age (≤50/≥51 years) (n=428) | 141 (33%)/287 (67%) |
Size (mm ≤20/>20) (n=427) | 212 (50%)/215 (50%) |
Tumour type (special type/lobular/ductal) (n=428) | 24 (6%)/23 (5%)/381 (89%) |
Grade (I/II/III) (n=426) | 55 (13%)/176 (41%)/195 (46%) |
Involved lymph node (Negative/positive) (n=420) | 231 (55%)/189 (45%) |
Oestrogen receptor status (ER-/ER+) (n=428) | 182 (43%)/246 (57%) |
Progesterone receptor status (PR-/PR+) (n=428) | 259 (61%)/169 (39%) |
ERBB2 amplification status (ERBB2-/ERBB2+) (n=426) | 336 (78%)/90 (21%) |
TN status (ER-,PR-,ERBB2-/ER+,PR+,ERBB2+) (426) | 118 (28%)/308 (72%) |
MCL-1 (High/low) (n=428) | 220 (51%)/208 (49%) |
